Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotheraphy in human bladder cancer cells

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 299-308

  Kamada, Masayuki ^a   So, Alan ^a   Muramaki, Mototsugu ^a   Rocchi, Palma ^a   Beraldi, Eliana ^a   Gleave, Martin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHAPERONE; HEAT SHOCK PROTEIN 27; MESSENGER RNA; OGX 427; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROTECTION; CELL STRESS; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; EXPERIMENTAL NEOPLASM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN TARGETING; REGULATORY MECHANISM; SEQUENCE ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BASE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846821658     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0417     Document Type: Article

References (49)

1. Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 1994;157:147-51.
2. Malmstrom PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987;21: 185-95.
3. Thurman SA, DeWeese TL. Multimodality therapy for the treatment of muscle-invasive bladder cancer. Semin Urol Oncol 2000; 18:313-22.
4. American Cancer Society. Cancer facts and figures. American Cancer Society 2006.
5. Raine CS, Wu E, Ivanyi J, Katz D, Brosnan CF. Multiple sclerosis: a protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab Invest 1996;75:109-23.
6. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099-105.
7. Love S, King RJ. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 1994; 69:743-8.
8. Ehrenfried JA, Herron BE, Townsend CM Jr., Evers BM. Heat shock proteins are differentially expressed in human gastrointestinal cancers. Surg Oncol 1995;4:197-203.
9. Langdon SP, Rabiasz GJ, Hirst GL, et al. Expression of the heat shock protein Hsp27 in human ovarian cancer. Clin Cancer Res 1995;1:1603-9.
10. Takashi M, Katsuno S, Sakata T, Ohshima S, Kato K. Different concentrations of two small stress proteins, αB crystallin and Hsp27 in human urological tumor tissues. Urol Res 1998;26:395-9.
11. Lebret T, Watson RW, Molinie V, et al. Heat shock proteins Hsp27, Hsp60, Hsp70, and Hsp90: expression in bladder carcinoma. Cancer 2003;98:970-7.
12. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 1993;85:1558-70.
13. Tomei LD, Kiecolt-Glaser JK, Kennedy S, Glaser R. Psychological stress and phorbol ester inhibition of radiation-induced apoptosis in human peripheral blood leukocytes. Psychiatry Res 1990;33:59-71.
14. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
15. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor gene expression and its relation to the estrogen-inducible Hsp27 heat shock protein in hormone refractory prostate cancer. Prostate 2000;45: 36-41.
16. Bruey JM, Paul C, Fromentin A, et al. Differential regulation of Hsp27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000; 19:4855-63.
17. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287-96.
18. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64:6595-602.
19. July LV, Beraldi E, So A, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004;3:223-32.
20. Grossman HB, Wedemeyer G, Ren L, Wilson GN, Cox B. Improved growth of human urothelial carcinoma cell cultures. J Urol 1986;136: 953-9.
21. Kiyama S, Morrison K, Zellweger T, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63:3575-84.
22. Yu RZ, Geary RS, Monteith DK, et al. Tissue disposition of 2′-0-(2-methoxy) ethyl modified antisense oligonucleoticles in monkeys. J Pharm Sci 2004;93:48-59.
23. Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 2005;7:171-9.
24. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001;3: 360-7.
25. Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-8.
26. Concannon CG, Orrenius S, Samali A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr 2001;9:195-201.
27. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004; 23:2907-18.
28. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73.
29. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-54.
30. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000;6:1655-63.
31. Bruey JM, Ducasse C, Bonniaud P, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000;2:645-52.
32. Charette SJ, Landry J. The interaction of Hsp27 with Daxx identifies a potential regulatory role of Hsp27 in Fas-induced apoptosis. Ann N Y Acad Sci 2000;926:126-31.
33. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, Rubinsztein DC. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 2002;11: 1137-51.
34. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J. Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J Cell Sci 1997;110:357-68.
35. Rene MJ, Pan Y, Singh S, et al. Heat shock protein 27 controls apoptosis by regulating AKT activation. J Biol Chem 2003;278:27828-35.
36. Parcellier A, Schmitt E, Gurbuxani S, et al. Hsp27 is a ubiquitinbinding protein involved in I-κBα proteasomal degradation. Mol Cell Biol 2003;23:5790-802.
37. Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005;65:11083-93.
38. Oesterreich S, Hilsenbeck SG, Ciocca DR, et al. The small heat shock protein Hsp27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res 1996;2: 1199-206.
39. Somji S, Garrett SG, Sens DA, ens MA. Heat shock protein 27 expression in human bladder. Urol Pathol 1998;9:1-15.
40. Rossi MR, Somji S, Garrett SH, Sens MA, Nath J, Sens DA. Expression of hsp 27, hsp 60, hsc 70, and hsp 70 stress response genes in cultured human urothelial cells (UROtsa) exposed to lethal and sublethal concentrations of sodium arsenite. Environ Health Perspect 2002; 110: 1225-32.
41. Kassem H, Sangar V, Cowan R, Clarke N, Margison GP. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 2002;101: 454-60.
42. McGarvey TW, Meng RD, Johnson O, El-Deiry W, Malkowicz SB. Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo. Urol Oncol 2001;6:155-62.
43. Miyake H, Hare I, Kamidono S, Gleave ME. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001;7:4245-52.
44. Miyake H, Hanada N, Nakamura H, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998; 16:933-43.
45. Chang FL, Lai MD. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines. Anticancer Res 2000;20:351-5.
46. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-79.
47. Duggan BJ, Gray S, Johnston SR, Williamson K, Miyaki H, Gleave M. The role of antisense oligonucleotides in the treatment of bladder cancer. Urol Res 2002;30:137-47.
48. Duggan BJ, Cotter FE, Kelly JD, et al. Antisense Bcl-2 oligonucleotide uptake in human transitional cell carcinoma. Eur Urol 2001;40:685-95.
49. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-19.